A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients with Dyslipidemia - PURSUIT

Study identifier:D7960C00006

ClinicalTrials.gov identifier:NCT06173570

EudraCT identifier:N/A

CTIS identifier:2023-506197-12-00

Study Complete

Official Title

A Phase IIb, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants with Dyslipidemia

Medical condition

Dyslipidemia

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD0780, Placebo

Sex

All

Actual Enrollment

428

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 19 Jan 2024
Primary Completion Date: 30 Sept 2024
Study Completion Date: 30 Sept 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

AstraZeneca K.K.

Inclusion and exclusion criteria